Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adrenal fatigue

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Adrenal fatigue. Displaying page 1 of 1.
    EudraCT Number: 2021-002528-18 Sponsor Protocol Number: RESCUE2131PE9 Start Date*: 2022-02-22
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency; A multicentre, randomised, double blinded, placebo-controlled clinical trial on health-re...
    Medical condition: Glucocorticoid-induced adrenal insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10001369 Adrenal insufficiency NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-006121-65 Sponsor Protocol Number: 65411807 Start Date*: 2021-08-31
    Sponsor Name:Odense University Hospital
    Full Title: STUDY PROTOCOL: A multi-centre, randomized, double-blinded, placebo controlled 1-year study to compare the effect of hydrocortisone and palcebo in patients with partial adrenal insufficiency after ...
    Medical condition: To investigate the effects of hydrocortisone replacement in participants with previous PMR and GCA, who are in GC-free remission and exhibit biochemical evidence of mild to moderate adrenal insuffi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10001369 Adrenal insufficiency NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005448-32 Sponsor Protocol Number: DIUR-006 Start Date*: 2016-07-20
    Sponsor Name:Diurnal Ltd
    Full Title: A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia (CAH)
    Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002039-32 Sponsor Protocol Number: PlenadrEMA/1.1/2014 Start Date*: 2014-09-02
    Sponsor Name:Rigshospitalet, Copenhagen University Hospital
    Full Title: PlenadrEMA study - Effect of modified-release compared to conventional hydrocortisone on fatigue, measured by Ecological Momentary Assessments; a pilot study to assess feasibility, responsiveness o...
    Medical condition: Secondary adrenal insufficiency due to hypopituitarism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10052382 Secondary adrenal insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000144-21 Sponsor Protocol Number: DIUR-016-AI Start Date*: 2022-01-14
    Sponsor Name:Diurnal Limited
    Full Title: A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® Versus Plenadren®, in Adrenal Insu...
    Medical condition: Adrenal Insufficiency (AI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10052381 Primary adrenal insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001104-37 Sponsor Protocol Number: ME/2011/3709 Start Date*: 2014-10-06
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia
    Medical condition: Addison's disease and Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10011195 Cortisol LLT
    17.0 100000004848 10020518 Hydrocortisone LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-001768-30 Sponsor Protocol Number: HYSS 3 Start Date*: 2006-01-04
    Sponsor Name:EM-kliniken
    Full Title: Comparison of 2 and 4 doses hydrocortison substitution with regard to plasma concentration and quality of life.
    Medical condition: We aim to study patients with cortisol deficiency caused by primary adrenal insufficiency (Addison’s disease of autoimmune origin).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004078-16 Sponsor Protocol Number: DOSCORT20092231 Start Date*: 2020-11-23
    Sponsor Name:Sahlgrenska University Hospital, Gothenburg
    Full Title: A dose-response study of markers of glucocorticoid action (DOSCORT)- A double-blind, randomized, two-period, two-dose, cross-over study in subjects with primary adrenal insufficiency
    Medical condition: Adrenal insufficiency e.g. Addison´s disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004679-36 Sponsor Protocol Number: 05 2015-001 Start Date*: 2006-12-13
    Sponsor Name:Laboratoire HRA Pharma
    Full Title: Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
    Medical condition: Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10014155 Ectopic corticotrophin syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016636-13 Sponsor Protocol Number: 113173 Start Date*: 2010-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients...
    Medical condition: First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-003605-55 Sponsor Protocol Number: 74556 Start Date*: 2021-01-15
    Sponsor Name:Erasmus MC - University Medical Centre
    Full Title: Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with oligometastatic disease
    Medical condition: Patients (18 – 75 years) who are diagnosed with adenocarcinoma of the oesophagus or GOJ with a resectable primary tumour and de-novo synchronous oligometastatic disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002407-32 Sponsor Protocol Number: CSOM230B2208E1 Start Date*: 2004-10-21
    Sponsor Name:NOVARTIS FARMA
    Full Title: Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease
    Medical condition: Treatment of Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10035109 Pituitary-dependent Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000987-80 Sponsor Protocol Number: ET19036 Start Date*: 2019-10-15
    Sponsor Name:Centre Léon Bérard
    Full Title: COTESARC - A multicentre Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarc...
    Medical condition: advanced/metastatic soft tissu sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005097-11 Sponsor Protocol Number: ETOP6-14 Start Date*: 2015-08-03
    Sponsor Name:ETOP (European Thoracic Oncology Platform)
    Full Title: A phase II trial evaluating the safety and efficacy of the addition of concurrent anti-PD-1 nivolumab to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B Non-Small...
    Medical condition: locally advanced stage IIIA/B NSCLC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 14:55:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA